ITLN1 modulates invasive potential and metabolic reprogramming of ovarian cancer cells in omental microenvironment

On July 15, 2020, professor Samuel C Mok from The University of Texas MD Anderson Cancer Center coauthored with professor Deepak Nagrath from University of Michigan published a paper on Nature communications. The paper titled ITLN1 modulates invasive potential and metabolic reprogramming of ovarian cancer cells in omental microenvironment.

The ELISA kit ((ITLN1, SEA933Mu) of Cloud-Clone brand was chosed to determine the concentation of ITLN1 in this article, we are so proud for supporting

Advanced ovarian cancer usually spreads to the omentum. However, the omental cell-derived molecular determinants modulating its progression have not been thoroughly characterized. Here, we show that circulating ITLN1 has prognostic significance in patients with advanced ovarian cancer. Further studies demonstrate that ITLN1 suppresses lactotransferrin's effect on ovarian cancer cell invasion potential and proliferation by decreasing MMP1 expression and inducing a metabolic shift in metastatic ovarian cancer cells. Additionally, ovarian cancer-bearing mice treated with ITLN1 demonstrate marked decrease in tumor growth rates. These data suggest that downregulation of mesothelial cell-derived ITLN1 in the omental tumor microenvironment facilitates ovarian cancer progression.

Ovarian cancer is one of the most common malignancies of the female reproductive system. Ovarian cancer early symptoms are not obvious, about 65% of patients have been diagnosed in the advanced stage, a high mortality rate. The 5-year survival rate was 92% for early diagnosis, but only 15% of patients were clinically diagnosed at this stage. Therefore, the survival rate of ovarian cancer depends on early diagnosis and treatment. Ovarian cancer biomarkers are characterized by simple sampling and convenient operation, which are considered as ideal indicators for early diagnosis and prognosis tracking.Cloud-Clone cloud provide multiple proteins, antibodies and ELISA kits of detection markers for Ovarian Cancer, which can be used in testing human, mouse, rat, porcine, caprine, etc.